Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients von Barlogie, Bart, Desikan, Raman, Eddlemon, Paul, Spencer, Trey, Zeldis, Jerome, Munshi, Nikhil, Badros, Ashrof, Zangari, Maurizio, Anaissie, Elias, Epstein, Joshua, Shaughnessy, John, Ayers, Dan, Spoon, Dan, Tricot, Guido

Volltext

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR ra... von Hari, Parameswaran, Reece, Donna E., Randhawa, Jasleen, Flomenberg, Neal, Howard, Dianna S., Badros, Ashrof Z., Rapoport, Aaron P., Meisenberg, Barry R., Filicko-Ohara, Joanne, Phillips, Gordon L., Vesole, David H.

Volltext

Final outcomes of escalated melphalan 280 mg/m 2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR r... von Hari, Parameswaran, Reece, Donna E, Randhawa, Jasleen, Flomenberg, Neal, Howard, Dianna S, Badros, Ashrof Z, Rapoport, Aaron P, Meisenberg, Barry R, Filicko-Ohara, Joanne, Phillips, Gordon L, Vesole, David H

Volltext

Effect of the Proteasome Inhibitor Bortezomib in Combination with “DT-PACE” on Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts) von Badros, Ashrof Z., Bolaños-Meade, Javier, Rapoport, Aaron, Ratterree, Bashi, Natt, Sabrina, Ruehle, Kathy, McNamara, Kathy, Cox, Edmund, Westphal, Sandy, Fenton, Robert, Meisenberg, Barry

Volltext

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts) von Badros, Ashrof Z., Goloubeva, Olga, Ratterree, Bashi, Natt, Sabrina, Rapoport, Aaron, Bolaños-Meade, Javier, Zhang, Ben, Zeldis, Jerry, Frankel, Stanley, Meisenberg, Barry, Zwiebel, James, Flaws, J., Tomic, D., Fenton, Robert

Volltext